Evidence map›Paper›PMID 25529753›Full record

ReviewMicrobes and infection2015

Advancements in the development of subunit influenza vaccines.

Naru Zhang, Bo-Jian Zheng, Lu Lu, Yusen Zhou, Shibo Jiang, Lanying Du

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microbes and infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mucosal Administration ofJournal of microbiology and biotechnology · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Adjuvant action of needle-shaped BC microfibrils.Cellulose (London, England) · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. An overview of current COVID-19 vaccine platforms.Computational and structural biotechnology journal · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Naru ZhangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Bo-Jian ZhengDepartment of Microbiology, University of Hong Kong, Pokfulam, Hong Kong.
Lu LuKey Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.
Yusen ZhouState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Shibo JiangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China. Electronic address: shibojiang@fudan.edu.cn.
Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. Electronic address: ldu@nybloodcenter.org.
New York Blood Center · USInstitute of Microbiology · CNShanghai Medical College of Fudan University · CNUniversity of Hong Kong · HK

Funding

B. subtilis spore-delivered M2e-FP-based mucosal universal influenza vaccinesR21AI111152 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2014 to 2015
$470k
NIAID NIH HHS R21 AI111152NIAID NIH HHS R21AI111152
6 · The paper itself

Abstract

The ongoing threat of influenza epidemics and pandemics has emphasized the importance of developing safe and effective vaccines against infections from divergent influenza viruses. In this review, we first introduce the structure and life cycle of influenza A viruses, describing major influenza A virus-caused pandemics. We then compare different types of influenza vaccines and discuss current advancements in the development of subunit influenza vaccines, particularly those based on nucleoprotein (NP), extracellular domain of matrix protein 2 (M2e) and hemagglutinin (HA) proteins. We also illustrate potential strategies for improving the efficacy of subunit influenza vaccines.

Indexed as

AnimalsHumansInfluenza A virusInfluenza VaccinesVaccines, SubunitInfluenza VaccinesVaccines, SubunitHemagglutininInfluenza A virusMatrix proteinNucleoproteinSubunit vaccines

Identifiers

PMID25529753
PMCPMC4336774
OpenAlexW2067173288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.